Ervogastat combination
MASH
Phase 2Planned 2027
Key Facts
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing novel therapeutics for MASH, formerly known as NASH. The company has successfully brought the first FDA-approved treatment for MASH to market in the U.S. and EU, marking a historic milestone in liver disease treatment. Madrigal's innovative THR-β agonist platform addresses the underlying causes of liver fibrosis and metabolic dysfunction, with multiple Phase 3 trials ongoing to expand treatment options for MASH patients.
View full company profileTherapeutic Areas
Other MASH Drugs
| Drug | Company | Phase |
|---|---|---|
| siRNA SLC25A5 | Novo Nordisk | Phase 1 |